Emergent BioSolutions EBS
NYSE EBS
$6.76 +0.21 (+3.21%)
At close: Sep 22, 2026 · 4:00 PM EDT

Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026)

Emergent BioSolutions (EBS) posted Income from Continuing Operations of -$180.2 million for Q2 2026, down 2750.0% on a QoQ basis from $6.8 million in Q1 2026, and down 1401.67% year-over-year from $13.8 million in Q2 2025.

Analysis

Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026) Analysis & Trends

Emergent BioSolutions has reported Income from Continuing Operations for 16 years, with the latest figure at -$180.2 million in Q2 2026.

  • On a quarterly basis, Income from Continuing Operations fell 1401.67% year-over-year to -$180.2 million in Q2 2026; TTM through Jun 2026 was -$176.8 million, a 226.74% decrease from a year earlier, with the FY2025 full-year figure at $52.6 million, up 127.6% from the prior year.
  • Income from Continuing Operations was -$180.2 million for Q2 2026 at Emergent BioSolutions, down from $6.8 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $114.8 million in Q3 2024, with the low at -$283.1 million in Q2 2024.
  • Average Income from Continuing Operations over 5 years is -$71.4 million, with a median of -$52.0 million recorded in 2023.
  • The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 4932.43% in 2023, then surged 655.56% in 2025.
  • Over 5 years, Income from Continuing Operations stood at -$67.0 million in 2022, then advanced by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then slumped by 74.44% to -$54.6 million in 2025, then plunged by 230.04% to -$180.2 million in 2026.
  • The last three Income from Continuing Operations figures came in at -$180.2 million (Q2 2026), $6.8 million (Q1 2026), and -$54.6 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 649.47 Bn 628.71 Bn 17.26 Bn 5.53 Bn
2 AbbVie 467.46 Bn 460.93 Bn 12.70 Bn 3.62 Bn
3 Merck 369.31 Bn 362.22 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 269.03 Bn 261.74 Bn 11.24 Bn 5.28 Bn
5 Pfizer 158.11 Bn 146.71 Bn 10.94 Bn -246.00 Mn
6 Bristol Myers Squibb 127.96 Bn 116.89 Bn 9.25 Bn 3.32 Bn
7 Sanofi 51.83 Bn 44.86 Bn 10.79 Bn 2.16 Bn
8 BeOne Medicines 41.33 Bn 36.23 Bn 1.53 Bn 237.01 Mn
9 Revolution Medicines 41.30 Bn 41.30 Bn - -644.37 Mn
10 Emergent BioSolutions 335.50 Mn 194.60 Mn 137.20 Mn -180.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -180.20 Mn
Mar 31, 2026 6.80 Mn
Dec 31, 2025 -54.60 Mn
Sep 30, 2025 51.20 Mn
Jun 30, 2025 -12.00 Mn
Mar 31, 2025 68.00 Mn
Dec 31, 2024 -31.30 Mn
Sep 30, 2024 114.80 Mn
Jun 30, 2024 -283.10 Mn
Mar 31, 2024 9.00 Mn
Dec 31, 2023 -49.50 Mn
Sep 30, 2023 -263.40 Mn
Jun 30, 2023 -261.40 Mn
Mar 31, 2023 -186.20 Mn
Dec 31, 2022 -67.00 Mn
Sep 30, 2022 -87.10 Mn
Jun 30, 2022 -56.40 Mn
Mar 31, 2022 -3.70 Mn
Dec 31, 2021 177.90 Mn
Sep 30, 2021 -32.70 Mn
API Access

Emergent BioSolutions Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=EBS&period=max&api_key=YOUR_API_KEY